![Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019]()
by Admin | Jan 17, 2019 | News & Opinions
HOUSTON, Jan. 17, 2019 /PRNewswire/ — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid...
![Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019]()
by Admin | Jan 15, 2019 | News & Opinions
Sanford Health is a contributing partner of the 2019 World Stem Cell Summit. Philanthropist Denny Sanford received the RMF Stem Cell Action “Leadership” Award, at the 2013 World Stem Cell Summit in San Diego. It was his vision and focused philanthropy that...
![Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019]()
by Admin | Jan 15, 2019 | News & Opinions
Who owns the brand “stem cells” ? Lofty scientific societies, such as the International Society for Stem Cell Research (ISSCR)? How about medical associations like the American Society for Plastic Surgeons (ASPS) or members of the International Federation...
![Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019]()
by admin | Jan 15, 2019 | News & Opinions
How profound is the coming age of cell and gene therapies? Answered simply, it will profoundly impact medicine and humanity. Converging “Future Shock” technologies. Societal change. How big? Think the Industrial Revolution- the Bronze Age- the discovery of...
![Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019]()
by admin | Jan 14, 2019 | News & Opinions
Accomplish your goals at World Stem Cell Summit & Phacilitate Leaders World, Jan. 22-25, Miami! Dear Colleague, With 2,000 attendees from 40 nations, the 14th World Stem Cell Summit and award-winning Phacilitate Leaders World conferences in Miami, Florida will...
by Admin | Jan 10, 2019 | News & Opinions
MIAMI – May 23, 2018 – Longeveron LLC, a biopharmaceutical company that develops stem cell therapies for age-related diseases, announced that it is currently recruiting for a Phase 1 clinical trial to evaluate the safety and efficacy of its allogeneic Mesenchymal Stem...
